Cashu FinanceCashu Finance
  • Terminal
  • Spotlight
  • Cashu Research
Log inSign Up
← Back to Terminal
  1. Stocks
  2. Healthcare
  3. NASDAQ
  4. ALDX

Market Cap: $41.24M

AT

Aldeyra The

ALDX
NASDAQUSD
Purchase ALDX
OverviewNewsAnalyst ReportsFinancialsPolitician TradesInsider TradesExecutive
Cashu FinanceCashu Finance

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

StocksAboutAdvertisersBrokersContact

Legal

Terms of ServicePrivacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Research is part of Cashu Technology Pty Ltd, which is an authorised representative (AR # 001318029) of Adviser Solutions Group Pty Ltd (ABN 88 601 875 521) (AFSL 485946) (ASG).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by Cashu Technologies Pty Ltd, any of their related body corporates or any other person. To the maximum extent possible, Cashu Technologies Pty Ltd, their related body corporates or any other person do not accept any liability for any statement in this material.

$0.6412
-$0.0005(-0.08%)
At close: Oct 28, 00:37 EDT

Recently from Cashu

Aldeyra Seeks FDA Feedback on Reproxalap After Multiple Complete Response Letters

Aldeyra Seeks FDA Feedback on Reproxalap After Multiple Complete Response Letters

Aldeyra Therapeutics (Ticker: ALDX) focuses on its dry eye disease candidate reproxalap as it seeks feedback from the FDA following three complete response letters (CRLs) questioning the efficacy of t…

Cashu Finance·5 months ago

Aldeyra Therapeutics Under Legal Investigation After FDA Rejection of New Drug Application

Aldeyra Therapeutics Faces Legal Scrutiny Amid FDA Setbacks Aldeyra Therapeutics, Inc. is currently at the center of an investigation by the Rosen Law Firm, which is exploring potential securities cla…

Cashu Finance·7 months ago

Aldeyra Therapeutics Faces Legal Challenges Following FDA Concerns About Reproxalap Efficacy

Aldeyra Therapeutics Under scrutiny: FDA Response Triggers Legal Investigations Aldeyra Therapeutics, a biopharmaceutical company focused on developing innovative therapies for ocular conditions, face…

Cashu Finance·7 months ago

Aldeyra Therapeutics Faces Setback as FDA Issues Complete Response Letter for Reproxalap Approval

Aldeyra Therapeutics Faces Regulatory Hurdles for Dry Eye Treatment Aldeyra Therapeutics encounters a significant setback as the FDA issues a Complete Response Letter (CRL) regarding its New Drug Appl…

Cashu Finance·7 months ago

Open

$2.21

Prev. Close

$0.6412

High

$2.36

Low

$2.21

Company Profile

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

CEOTodd C. Brady
SectorHealthcare
IndustryBiotechnology
Employees6
IPO DateMay 2, 2014
ExchangeNASDAQ
Exchange NameNASDAQ
CurrencyUSD
Headquarters & Contact
Address131 Hartwell Avenue
City / State / ZIPLexington, MA, 02421
CountryUnited States
Phone781 761 4904
Websitehttps://www.aldeyra.com